dc.creatorSan Martín, Alvaro
dc.creatorPagani, Mario Rafael
dc.date.accessioned2017-12-12T19:07:47Z
dc.date.accessioned2018-11-06T11:46:48Z
dc.date.available2017-12-12T19:07:47Z
dc.date.available2018-11-06T11:46:48Z
dc.date.created2017-12-12T19:07:47Z
dc.date.issued2014-05
dc.identifierSan Martín, Alvaro; Pagani, Mario Rafael; Understanding intellectual disability through RASopathies; Elsevier; Journal of Physiology; 108; 4-6; 5-2014; 232-239
dc.identifier0928-4257
dc.identifierhttp://hdl.handle.net/11336/30320
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1859440
dc.description.abstractIntellectual disability, commonly known as mental retardation in the International Classification of Disease from World Health Organization, is the term that describes an intellectual and adaptive cognitive disability that begins in early life during the developmental period. Currently the term intellectual disability is the preferred one. Although our understanding of the physiological basis of learning and learning disability is poor, a general idea is that such condition is quite permanent. However, investigations in animal models suggest that learning disability can be functional in nature and as such reversible through pharmacology or appropriate learning paradigms. A fraction of the cases of intellectual disability is caused by point mutations or deletions in genes that encode for proteins of the RAS/MAP kinase signaling pathway known as RASopathies. Here we examined the current understanding of the molecular mechanisms involved in this group of genetic disorders focusing in studies which provide evidence that intellectual disability is potentially treatable and curable. The evidence presented supports the idea that with the appropriate understanding of the molecular mechanisms involved, intellectual disability could be treated pharmacologically and perhaps through specific mechanistic-based teaching strategies.
dc.languageeng
dc.publisherElsevier
dc.relationinfo:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S0928425714000205
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240771/
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.jphysparis.2014.05.003
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectLEARNING DEFICIT
dc.subjectRAS/MAP KINASE SIGNALING PATHWAY
dc.subjectPHARMACOLOGICAL TREATMENT
dc.subjectLEARNING STRATEGIES
dc.subjectPHENOTYPIC REVERSION
dc.titleUnderstanding intellectual disability through RASopathies
dc.typeArtículos de revistas
dc.typeArtículos de revistas
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución